Pharmacologic resistance in colorectal cancer: a review

Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in both men and women worldwide. This is in spite of widespread, effective measures of preventive screening, and also major advances in treatment options. Despite advances in cytotoxic and targeted therapy, resistan...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic Advances in Medical Oncology 2016-01, Vol.8 (1), p.57-84
Main Authors: Hammond, William A., Swaika, Abhisek, Mody, Kabir
Format: Article
Language:English
Subjects:
Chemotherapy
Colorectal cancer
Colorectal carcinoma
Cytotoxicity
Metastases
Reviews
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in both men and women worldwide. This is in spite of widespread, effective measures of preventive screening, and also major advances in treatment options. Despite advances in cytotoxic and targeted therapy, resistance to chemotherapy remains one of the greatest challenges in long-term management of incurable metastatic disease and eventually contributes to death as tumors accumulate means of evading treatment. We performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, and the ASCO Annual Symposium abstracts through June 2015 for the purpose of this review. We discuss the current state of knowledge of clinically relevant mechanisms of resistance to cytotoxic and targeted therapies now in use for the treatment of CRC.
ISSN:1758-8340
1758-8359
1758-8359
DOI:10.1177/1758834015614530